Health Economics and Outcomes Research
A multidisciplinary approach to design, execute, and analyze new interventions is required for generating relevant evidence for different stakeholders, reimbursement agencies, and health authorities. Health Economics and Outcomes Research (HEOR) is often foreseen as a complex process due to factors like different approaches to healthcare delivery and the varying cost of healthcare resources in various states. At OrciMed, we emphasize the economic impact of treatments, diseases, and conditions, along with the direct and indirect costs due to medical expenditures and costs associated with disability and loss of work respectively.
Our expertise includes comprehensive literature reviews, clinical evidence generation, and various methodologies for economic modelling that draw on diverse data sources from global markets. Our experts are qualified professionals in health policy, pharmacy, and medicine with distinguished expertise in economics, psychometrics, epidemiology, biostatistics, and econometrics. Our HEOR team can also supports customers through services including management of economic endpoints in clinical trials, treatment pattern analyses, portfolio planning, trial/market simulation modeling, pricing and market access research, Patient Reported Outcome (PRO) studies, global cost-effectiveness models, and value dossiers. Our expert team can develop suitable solutions based on customer requirement that can be as simple as a cost calculator to assess treatment costs and costs of adverse events to various models to evaluate economic implications and compare customer products with comparators.
While Systematic Literature Reviews (SLRs) are standard studies designed to addresses specific research questions by collecting and summarizing information from existing clinical research, Targeted Literature Reviews (TRAs) are non-systematic literature review that focuses on specific topics and are more informative. We adhere to guidelines defined by authorities and follow a pragmatic and technical methodology to deliver client specific requirements that are reproducible and reliable. Our experts generating real-world evidence, real-world evidence, Patient Reported Outcomes (PROs) and Patient reported outcome measures (PROMs) along with electronic format migration, translation and licensing.
Epidemiology focuses on understand the causes and incidence of disease. Prevalence and incidence are measures of disease frequency used to resolve varying research problems. While incidence indicate number new cases, frequency indicates number of existing cases. We expertise in systemic literature reviews (SLR) and targeted literature reviews (TLR) help our customers effectively measure disease frequency, health outcomes over time and population groups to derive effective treatment, prevention and care. We are experts in prevalence, the risk, and the incidence rate measures and advise our customers on selection of most suitable measures specific to their study populations.
Health Related Quality of Life (HRQOL) as an outcome plays a pivotal role in assessing public health rather than the traditional measures and help in devising better interventions to avoid serious outcomes and progress their situation. Our experts can deliver high quality Systematic Literature Research that enables need based analysis for policies, identify interventions via strategic planning and monitor its effectiveness. Our process is configured based on thorough understand of guidelines from Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) and Institute of Medicine enabling our clients to effectively determine economic burden of illness and gain insights in HRQOL and risk factor relationship. We can partner with our client to develop and validate unique HRQOL measure for their specific patient population and health outcome.
Our experts develop insights with their proficiency in various economic models like Partitioned survival analysis, Markov Models, discrete event simulation (DES), decision trees along with Multiple Criteria Decision Analysis (MCDA) that help our client attain their HEOR goals. Our budget impact models (BIM) development process ensures effortlessly budget impact analysis during introduce new products introduction. Our expertise in cost analysis has ensured our processed out to be detailed with ready data for improvement resource distribution and planning resulting in quick and enhance decision making. We provide expert guidance with a strong background of health technology assessment (HTA) agency requirements for HTA submissions and method selection for economic evaluation like cost-benefit analysis, cost-utility analysis, cost-minimization analysis and cost-effective analysis (CA) and incremental CA ratio (ICER).
Corporate Office
©2023. OrciMed Life Sciences. All Rights Reserved.